Pharma buyout. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. ENDPOINTS MANUFACTURING Thu at 2 PM ET. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. | Just months after striking its $11. I covered Aurinia Pharmaceuticals (NASDAQ:AUPH) on January 5, a day after its patent dispute got settled with Sun Pharma. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by Apr 8, 2024 · After Novo Holdings set the stage for a $16. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Fusion’s pipeline is led by a PSMA Dec 21, 2022 · Any of these would find a buyout or even partnering with MDGL immensely beneficial. THOUSAND OAKS, Calif. P. 3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys Dec 14, 2023 · The buyout of the antibody-drug conjugate specialist has doubled Pfizer’s pipeline to 60 programs. ↑ X Mar 26, 2024 · GW Pharmaceuticals and its leaders will pay $7. 8% on Jun 30, as management announced that it is exploring strategic alternatives for the company’s future. Mar 28, 2023 · Rare diseases and cancer are constantly featured in the biopharma M&A landscape. The bad: It's going to cost the generics . December. and Canadian rights to the drug in December. Now, one biotech company with a presence in both areas has reportedly caught Big Pharma’s interest. ) Dec 13, 2021 · Pfizer said on Monday it would buy drug developer Arena Pharmaceuticals for $6. The same number previously professed an interest in oncology medications. Aug 22, 2022 · The pharmaceutical merger and acquisition (M&A) scene is heating up. Morgan indicates early-stage startups are getting smaller upfront payments in alliances than a few years ago, a trend industry insiders attribute to weaker leverage in deal talks. Apr 10, 2024 · This page is intended as an educational resource for U. 00 per share in cash, upon closing the deal. 4 Aug 13, 2024 · BioPharma Dive is tracking M&A activity below. It’s also the third recent large transaction involving a maker of radiopharmaceuticals, following Eli Lilly’s $1. They have the best in class CD-20 for MS and just beat earnings of over 40 million for Q4 and total Gilead Completes Acquisition of Kite Pharma. See full list on fool. In May of last year, Pfizer stepped up its game with an $11. Apr 18, 2023 · BridgeBio draws buyout interest from Big Pharma: Bloomberg Prometheus will give Merck more of a presence in immunology with PRA023, an anti-TL1A monoclonal antibody for ulcerative colitis and About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050) Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. 05, 2024 3:27 PM ET Aurinia Pharmaceuticals Inc. 9 Billion -- Immediately Positions Gilead as a Leader in Cell Therapy---- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U. 80 per share Apr 19, 2023 · Besides Alnylam, the RBC team sees fellow RNAi player Arrowhead Pharmaceuticals as a good buyout target, too. A total May 27, 2024 · ChrysCapital Pharma Buyout Deals Formulation Business $1. ENDPOINTS WEEKLY Sat at 6 AM ET. Speaking to this point, Pfizer recently doled out $5. Concert investors will also receive a so-called contingent value right, or CVR, that could pay them an additional $3. Nov 30, 2022 · As for Sanofi, the French pharma is a well-established rare disease player since its $20 billion buyout of Genzyme more than a decade ago. and Expedited Review in the EU -- Feb 3, 2021 · Earlier this year, Jazz Pharmaceuticals floated a "dramatic" shift to new drug revenue by 2022—a plan buoyed by its own cancer and sleep disorder launches in 2019 and 2020, and a fourth targeted fo A ctinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H. The Britain-based pharmaceutical company said that the buyout Mar 24, 2022 · The good news for Sun Pharma is that it's closed the books on one more legal problem it inherited from its Ranbaxy Laboratories buyout eight years ago. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start Mar 20, 2024 · Fusion Pharmaceuticals FUSN signed a definitive agreement with AstraZeneca AZN. Follow. By Kevin Dunleavy May 30, 2023 10:48am. The company counts Johnson Nov 30, 2020 · Sunesis Investor and Media Inquiries: Maeve Conneighton: Par Hyare: Argot Partners: Sunesis Pharmaceuticals Inc. 3 billion acquisition of the Jun 26, 2024 · With a market cap of $1. 5 million to end shareholder allegations that they filed a deficient proxy statement to win votes for Jazz Pharmaceuticals PLC’s 2021 buyout of the cannabinoid drugmaker. Though the two companies were close to an agreement in September, Allergan took a step back Mar 26, 2022 · Licensing a successful drug is all fine and good, but it's usually more lucrative to own the whole thing. and Pfizer on a list of pharma companies that have spent mightily to acquire ADC programs. @wrynot the talk about buyout here is alteast 5 years Apr 18, 2024 · Future Pak, a 47-year-old, privately-held, Michigan-based contract manufacturer which specializes in solid dose packaging of pharmaceuticals, had offered to buy out Vanda at a share price of Feb 15, 2024 · As of early 2024, the largest deal in pharmaceutical industry history was Pfizer’s acquisition of Warner-Lambert for nearly 90 billion U. 5 Billion Valuations Indian Pharma Private Equity Firm Acquisitions Gynaecology (Catch all the Business News , Breaking News , Budget 2024 Events and Latest News Updates on The Economic Times . Sep 8, 2017 · How Kite came from a position of strength to get Gilead to boost its buyout price by 42% By Arlene Weintraub Sep 8, 2017 10:33am immuno-oncology M&A Arie Belldegrun CAR-T Dec 3, 2021 · Shares of Aurinia Pharmaceuticals Inc. 8 billion buyout of Horizon, they came quickly. has telegraphed its plans to cut back at its newly acquired unit. , Oct. 1 billion takeout of RayzeBio in December. Biogen ( BIIB -0. 212-600-1902: 650-266-3784 Viracta Investor Inquiries: Dec 13, 2021 · Pfizer has agreed to acquire Arena Pharmaceuticals for about $6. MDGL is at $4bn now. 50 per share in cash, representing a transaction equity value of approximately $27. The pharmaceutical merger and acquisition (M&A) scene is heating up. Jul 15, 2024 · J&J’s CAR-T partner Legend Biotech reportedly receives buyout offer. Jan 22, 2018 · Celgene’s $87-per-share agreement is within Jefferies’ expected $7 billion to $9. S. The multiple sclerosis treatment is Juvisé’s first patent-protected compound. 5 billion buyout of contract manufacturing giant Catalent earlier this year, its parent company is giving antitrust officials more time for their review Apr 3, 2016 · Cory Renauer:Now that Ireland-domiciledJazz Pharmaceuticals stock has left the stratosphere, it's at the top of my potential big pharma buyout list. Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye. | After a slow 2022, will we see a return to form for biopharma M&A? And, if so Mar 5, 2024 · Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed. Kala’s biologics-based investigational therapies utilize Kala’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform. 27, 2023 7:03 AM ET Theseus Pharmaceuticals, Inc. 10 top M&A targets in biotech for 2023. Two months after closing the deal, the Indian drugmaker has revealed (PDF) a blood clot has triggered a May 30, 2023 · Persistent Sun Pharma ready to complete Taro buyout—16 years after initial offer. AUPH gained 13. The acquisition, announced by GSK on Tuesday , marks a rapid return on investment for Aiolos’ blue-chip backers, which included Atlas Venture and Bain Capital Life Sciences. Biotech Beast. Sun Pharmaceuticals Taro Pharmaceuticals Generics price fixing. 8/09/2024 Track the latest trends and leading stocks in the biotech and pharmaceutical industries. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. 27 billion and an FDA-approved therapy, Verona could be viewed as a potential buyout target, and GSK would be a good fit, given its experience with respiratory disease With pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships Recent data from J. This list is based on notes to investors and comments in news outlets. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116. 89. Nov 30, 2022 · Analysts have been talking up a buyout of Mirati by a big pharma, with Merck, Pfizer, Bristol Myers Squibb and AstraZeneca all mentioned. Mar. Nov 30, 2023 · AbbVie is expanding its investment in targeted cancer medicines, announcing Thursday a $10. (AUPH) Stock 105 Comments 1 Like. The company makes a lupus nephritis treatment that could Feb 3, 2021 · Earlier this year, Jazz Pharmaceuticals floated a "dramatic" shift to new drug revenue by 2022—a plan buoyed by its own cancer and sleep disorder launches in 2019 and 2020, and a fourth targeted fo Mar 5, 2024 · Juvisé Pharmaceuticals has purchased the global commercial rights outside the U. These two biotechs have repeatedly been Dec 22, 2023 · We’ll be keeping an eye out for everything from the Big Pharma bolt-ons and blockbusters to the reverse mergers and biotech-on-biotech buyouts. 00 per Share of Common Stock, Including Upfront Cash Payment of $2. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health. 7 billion in a deal that validates the San Diego biotech’s plan to reshape itself around a portfolio of inflammation drugs. Dec 22, 2023 · We’ll be keeping an eye out for everything from the Big Pharma bolt-ons and blockbusters to the reverse mergers and biotech-on-biotech buyouts. The Jul 3, 2023 · Aurinia Pharmaceuticals AUPH rose almost 5. 96%) is an intriguing buyout play thanks to its FDA-approved lupus nephritis (LN) medication, Lupkynis. . Aug 28, 2017 · ENDPOINTS PHARMA Daily at 3:30 PM ET. Jul 31, 2023 · A juicy buyout offer with a steep premium is what sent Reata Pharmaceuticals' stock price through the roof last week. C. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on Feb 12, 2024 · Roughly half a year after Biogen’s $7. healthcare professionals. Jan 9, 2024 · Over the span of five months, biotechnology startup Aiolos Bio launched, raised initial funding from venture investors and negotiated a $1 billion buyout by GSK. 6 Jun 30, 2023 · Aurinia Pharmaceuticals said it's exploring strategic alternatives, including a potential buyout, leading AUPH stock to surge Friday. Mar 19, 2024 · Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations and desire entry into new markets. Dec 12, 2022 · Amgen will buy Horizon Therapeutics for $27. has one valuable asset and a developing but early stage pipeline, and the company has a good deal of cash. 7 billion in cash. Mar 19, 2024 · The deal is the 11th biopharmaceutical buyout in 2024, adding to the sector’s fastest M&A start in at least six years, according to BioPharma Dive data. Jan 23, 2023 · Per the terms of the definitive merger agreement, Sun Pharma is expected to initiate a tender offer to acquire all outstanding shares of Concert for $8. Buy the report here. Licensing. In response, HZNP stock surged to an eight-month high. The deal involved the acquisition of Theseus common stock at $3. Mar 11, 2022 · Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with immuno-inflammatory diseases Pfizer Inc. Madrigal Pharmaceuticals, Inc. 2 billion buyout of GW Pharma in 2021. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Jan 9, 2023 · AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. Wainwright highlighted its buyout potential after its peer in the radiopharma space, Fusion Pharma , agreed to be acquired by Mar 1, 2019 · Of 22 potential buyers ranging from AbbVie to Takeda Pharmaceutical , 18 are interested in immunology specialists. 8 billion in the biggest biopharma deal of the year. Pfizer's $43B buyout of ADC specialist Seagen is a done deal Fierce Pharma May 21, 2024 · GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q1 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. 6 billion to scoop up Biohaven Pharma’s CGRP inhibitor portfolio just months after Dec 1, 2023 · Just last week, Tang Capital reached out to Theseus Pharmaceuticals with a similar buyout offer on behalf of Concentra. But some of Sanofi’s recent M&A moves haven’t panned Mar 19, 2024 · AstraZeneca is adding to the explosion of interest in radiopharmaceuticals, inking a $2 billion buyout to meld Fusion Pharmaceuticals with its cancer unit. 5 billion May 2, 2023 · Sun Pharma’s $576 million Concert Pharmaceuticals buyout has rapidly run onto the rocks. Nov 7, 2014 · Concerns over those inventory levels stopped the Allergan takeover in its tracks, according to the WSJ. Dec 30, 2021 · These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. 7 billion acquisition of Arena Pharmaceuticals Mar 14, 2024 · Such forward-looking statements include, but are not limited to, the ability of AstraZeneca and Amolyt Pharma to complete the transactions contemplated by the acquisition agreement, including the parties’ ability to satisfy the conditions set forth in the acquisition agreement, statements about the expected timetable for completing the Nov 30, 2022 · Analysts have been talking up a buyout of Mirati by a big pharma, with Merck, Pfizer, Bristol Myers Squibb and AstraZeneca all mentioned. Jan 3, 2024 · With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. 4 billion deal for Point Biopharma in October and Bristol Myers Squibb’s $4. The company hasn't made any final decisions, Bloomberg notes. 3 billion in cash. 8 billion. Aug 15, 2023 · Speculation that Stada Arzneimittel may be looking for a buyout has largely been confirmed after the company’s CEO said as much in a recent German-language news story. ENDPOINTS FDA+ Wed at 2 PM ET. Summary. com Aug 13, 2024 · BioPharma Dive is tracking M&A activity below. 7 billion and Trillium Therapeutics for $2. The list of Acadia-sponsored publications below may contain information about doses, uses, formulations and populations different from product labelling or contain information about investigational compounds or uses not approved by the FDA. Apr 10, 2023 · Despite the slowdown in volume, deal value logged a record year, with private equity investors focusing buyout and add-on activity on pharma services. As a result of the sizable market for safe and effective LN TOKYO -- Taisho Pharmaceutical Holdings on Friday announced an offer by management to take the company private, looking to facilitate a pivot toward online and overseas sales of its mainstay over Mar 24, 2023 · Eoneren. 05K Followers. Per the agreement terms, the pharma giant will acquire all outstanding shares of Fusion for $21 per share in cash Nov 25, 2019 · Driven by a landmark cardiovascular outcomes trial that could spell blockbuster sales for its fish-oil derivative, Vascepa, Amarin has been a darling for pharma M&A speculators. Arrowhead has three late-stage candidates, RBC noted. 02% ) agreed to buy the drugmaker for $7. Read why I rate AUPH stock a Hold here. [31] 20 2014 Monsanto Company Inc. Fresh patents were also applied for or granted in the US (notice Mar 13, 2023 · In that year, Pfizer snapped up cancer specialists Arena Pharmaceutical for $6. These two biotechs have repeatedly been Feb 1, 2024 · It includes 10 biopharma companies that analysts and other market watchers have seen as buyout targets in recent months. (THRX) Stock By: Dulan Lokuwithana , SA News Editor Maksim Labkouski Oct 6, 2023 · Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines. dollars in 2000. Pfizer in 2022 shelled out $11. Jan 18, 2024 · Persistent Sun Pharma ready to complete Taro buyout—16 years after initial offer In May of last year, Sun revealed that it had offered to buy outstanding shares of the company for $38 each, with Aug 28, 2017 · August 28, 2017. Gilead Sciences to Acquire Kite Pharma for $11. Pfizer will buy Arena for $100 per share in cash, more than double the biotech’s closing price on Friday. 2% on Dec 2, following fresh rumors of a potential buyout. AUPH will consider a range of options Jun 6, 2023 · Two life sciences investment firms have agreed to acquire Paratek Pharmaceuticals in a take-private deal, betting that they can accelerate the sales of an antibiotic the biotechnology company has struggled to profitably market. March 26 Jan 30, 2023 · 2022 was a challenging year for pharma and life sciences M&A, according to PwC—and that’s putting it kindly. BREAKING NEWS ALERTS 2-3 times a week. Apr 26, 2023 · Aurinia Pharmaceuticals (AUPH-1. To this end, Pfizer recently completed a $6. Sep 8, 2017 · How Kite came from a position of strength to get Gilead to boost its buyout price by 42% By Arlene Weintraub Sep 8, 2017 10:33am immuno-oncology M&A Arie Belldegrun CAR-T Nov 30, 2023 · With the buyout, AbbVie is rejoining the likes of AstraZeneca, BioNTech, Gilead Sciences, GSK, Merck & Co. 8. Jun 6, 2023 · Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3. has about $153mn in cash reserves as of the last quarter Nov 30, 2023 · AbbVie is expanding its investment in targeted cancer medicines, announcing Thursday a $10. Apr 13, 2022 · Shares of Antares Pharma surged more than 47% in premarket trading Wednesday after the specialty pharmaceutical company agreed to be bought by Halozyme Therapeutics in a cash deal valued at $960 Dec 21, 2023 · Mountain RockOne you should take a look at is TG Therapeutics (TGTX) for a huge buyout. Vanda Pharmaceuticals bought the U. Its enterprise value -- a metric that accounts Jan 3, 2024 · With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. Mar 30, 2022 · Just months after striking its $11. Syngenta AG: 40 51 Monsanto weighed $40 billion unsolicited bid for Swiss rival, Syngenta aiming to avoid US Apr 21, 2022 · These biopharma companies could end up as attractive buyout targets in 2022 April 20, 2022 By Shanthi Rexaline Apr 21, 2022, 8:10 am EDT Intercept Pharma (NASDAQ: ICPT): Dec 12, 2022 · Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war By Fraiser Kansteiner Dec 12, 2022 8:20am Amgen Horizon Therapeutics Johnson & Johnson Sanofi BioCryst Pharmaceuticals, Inc. 50 per share if the hair loss drug hits certain milestones. 5 billion deal for Acceleron Pharma, Merck & Co. and Canada to Ponvory (ponesimod) from Johnson & Johnson’s Actelion Pharmaceuticals. 9 billion that Gilead Sciences paid for Juno’s CAR May 7, 2024 · Privately held contract manufacturer Future Pak said on Tuesday it will sweeten its buyout offer for Vanda Pharmaceuticals to include contingent value rights, in addition to the proposed offer Jul 11, 2022 · About Kala Pharmaceuticals, Inc. 3 billion. Biogen cut 113 positions from Reata Pharmaceuticals just weeks after closing its $7. While 2023 didn’t bring buyouts on the scale of Bristol Myers Squibb's massive Celgene acquisition or AbbVie’s $63 billion buyout of Allergan, the industry appears to have shaken off some of the Valeant Pharmaceuticals: Allergan, Inc: 45 58 Valeant Pharmaceuticals and activist investor Bill Ackman offered to buy Botox maker Allergan, proposing a cash-and-stock deal worth about $152. Jan 19, 2023 · Sun Pharma will pay $8 for each share of Concert, a 16% premium to the target’s closing stock on Wednesday. Aug 22, 2022 · These three biotech companies could be headed for a buyout soon. 15 per Share and a Nov 23, 2022 · Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle . Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. 4 billion to acquire Global Blood Therapeutics for its sickle cell disease 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start Jan 25, 2009 · It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. Oct 20, 2023 · That might include splitting off its cannabinoid business, which Jazz acquired through its $7. 5 billion range for the transaction, and less than the $11. Jan 28, 2024 · Speculation about Aurinia Pharmaceuticals buyout continues as the company continues to review strategic options. Dec 13, 2020 · AstraZeneca announced that it has agreed to acquire US drugmaker Alexion Pharmaceuticals in a cash and stock deal worth $39 billion. While 2023 didn’t bring buyouts on the scale of Bristol Myers Squibb's massive Celgene acquisition or AbbVie’s $63 billion buyout of Allergan, the industry appears to have shaken off some of the Nov 27, 2023 · Theseus Pharmaceuticals discloses buyout interest Nov. Private equity continues to shoulder “molecule risk” with growth-stage/crossover pharma, raising dedicated life sciences funds. 1 billion deal to acquire ImmunoGen, a pioneer in the field of so-called antibody-drug conjugates, and its newly approved ovarian cancer treatment Elahere. Oct 24, 2023 · In the case of Amgen’s $27. rwuiepkkqeswnrozcjaniuhoxlqqonzplzyjgxjiybfhapcu